Future directions for intrathecal pain management: A review and update from the interdisciplinary polyanalgesic consensus conference 2007

Neuromodulation

Volumn 11, Issue 2, 2008, Pages 92-97

  Deer, Timothy ^a,b   Krames, Elliot S ^a   Hassenbusch, Samuel ^a   Burton, Allen ^a   Caraway, David ^a   Dupen, Stuart ^a   Eisenach, James ^a   Erdek, Michael ^a   Grigsby, Eric ^a   Kim, Phillip ^a   Levy, Robert ^a   McDowell, Gladstone ^a   Mekhail, Nagy ^a   Panchal, Sunil ^a   Prager, Joshua ^a   Rauck, Richard ^a   Saulino, Michael ^a   Sitzman, Todd ^a   Staats, Peter ^a   Stanton Hicks, Michael ^a   Stearns, Lisa ^a   Dean Willis, K ^a   Witt, William ^a   Follett, Kenneth ^a   Huntoon, Mark ^a   Liem, Leong ^a   Rathmell, James ^a   Wallace, Mark ^a   Buchser, Eric ^a   Cousins, Michael ^a   Ver Donck, Ann ^a   more..

^a West Virginia University ^*

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Expert panel; Intrathecal; IT agents; Polyanalgesic

Indexed keywords

ADENOSINE; ANALGESIC AGENT; CGX 1160; CLONIDINE; CONOTOXIN; DIZOCILPINE; GABAPENTIN; MORPHINE; OCTREOTIDE; OMEGA CONOTOXIN; OMEGA CONOTOXIN CVID; OMEGA CONOTOXIN MVIIA; OPIATE; PHYSOSTIGMINE; PLACEBO; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; XEN 2174;

ABSENCE OF SIDE EFFECTS; ALLODYNIA; ANALGESIA; ARTICLE; CLINICAL TRIAL; CONSENSUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; INTRACTABLE PAIN; LOW DRUG DOSE; NEUROPATHIC PAIN; NONHUMAN; POSTOPERATIVE PAIN;

EID: 41749102879     PISSN: 10947159     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1403.2008.00148.x     Document Type: Article

References (34)

1. Bennett G, Burchiel K, Buchser E et al. Clinical guidelines for intraspinal infusion: report of an expert panel. J Pain Symptom Manage 2000 20: S37 S43.
2. Hassenbusch S, Portenoy R, Cousins M et al. Polyanalgesic consensus conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel. J Pain Symptom Manage 2004 27: 540 563.
3. Deer T, Krames E, Hassenbusch S et al. Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery - report of an interdisciplinary expert panel. Neuromodulation, 2007 10: 300 328.
4. Deer T, Krames E, Hassenbusch S et al. Management of IT catheter-tip inflammatory masses: an updated consensus statement from an expert panel. Neuromodulation 2008 11: 75 89.
5. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy - a survey of clinical trends in decision making. J Pain Symptom Manage 2000 20: S4 S11.
6. Bennett G, Deer T, Du Pen S et al. Future directions in the management of pain by intraspinal drug delivery. J Pain Symptom Manage 2000b 20: S44 S50.
7. Adis Data Information BV. Neutralizing neuropathic pain: promising new targets point to future therapies. Pharmaceutical & Diagnostic Innovation 2004 2: 15 19.
8. Mehdiratta R, Saberwal G. Bio-business in brief: the case of conotoxins. Curr Sci 2007 92: 39 45.
9. Bowersox SS, Gadbois T, Singh T, Pettus M, Wang YX, Luther RR. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996 279: 1243 1124.
10. 2+ channels, KATP channels or N-methyl-d-aspartic acid receptors? Anesth Analg 2006 102: 182 187.
11. Coderre TJ, Kumar N, Lefebvre CD, Yu JS. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem 2005 94: 1131 1139.
12. Chen SR, Pan HL. Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids. Anesthesiology 2004 100: 676 682.
13. Lin JA, Lee MS, Wu CT et al. Attenuation of morphine tolerance by intrathecal gabapentin is associated with suppression of morphine-evoked excitatory amino acid release in the rat spinal cord. Brain Res 2005 1054:167 173.
14. Yoon MH, Bae HB, Choi JI et al. Evaluation of interaction between intrathecal adenosine and MK801 or NBQX in a rat formalin pain model. Pharmacology 2005 75:157 164.
15. Yoon MH, Bae HB, Choi JI. Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test. Anesth Analg 2005 101:1417 1421.
16. Rane K, Segerdahl M, Karlsten R. Intrathecal adenosine increases spinal cord blood flow in the rat: measurements with the laser-Doppler flowmetry technique. Acta Anaesthesiol Scand 2004 48:1249 1255.
17. Yoon MH, Bae HB, Choi JI, Kim SJ, Chung ST, Kim CM. Roles of adenosine receptor subtypes in the antinociceptive effect of intrathecal adenosine in a rat formalin test. Pharmacology 2006 78:21 26.
18. Kekesi G, Dobos I, Benedek G, Horvath G. The antinociceptive potencies and interactions of endogenous ligands during continuous intrathecal administration: adenosine, agmatine, and endomorphin-1 Anesth Analg 2004 98:420 426.
19. Eisenach JC, Hood DD, Curry R, Sawynok J, Yaksh TL, Li X. Intrathecal but not intravenous opioids release adenosine from the spinal cord. J Pain 2004 5:64 68.
20. Li X, Eisenach JC. Adenosine reduces glutamate release in rat spinal synaptosomes. Anesthesiology 2005 103:1060 1065.
21. Hayashida M, Fukuda K, Fukunaga A. Clinical application of adenosine and ATP for pain control. J Anesth 2005 19:225 235.
22. Sharma M, Mohta M, Chawla R. Efficacy of intrathecal adenosine for postoperative pain relief. Eur J Anaesthesiol 2006 23:449 453.
23. Eisenach J, Hood D, Curry R. Phase I safety assessment of intrathecal injection of an American formulation of adenosine in humans. Anesthesiology 2002 96:24 28 M, Segerdahl M, Arnér S, Sollevi A. The safety and efficacy of intrathecal adenosine in patients with chronic neuropathic pain. Anesth Analg 1999 89:136.
24. Deer T, Kim C, Bowman R et al. The use of continuous intrathecal infusion of octreotide in patients with chronic pain of noncancer origin: an evaluation of side-effects and toxicity in a prospective double-blind fashion. Neuromodulation 2005 8:171 175.
25. Tsai Y, So E, Chen H, Wand L, Chen C. Effect of intrathecal octreotide on thermal hyperalgesia and evoked spinal c-fos expression in rats with sciatic constriction injury. Pain 2002 99:407 413.
26. Su XMB, Burton MBGF, Gebhart GF. Effects of octreotide on responses to colorectal distension in the rat. Gut 2001 48:676 682.
27. Paice JA, Penn RDMD, Kroin JS. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Case Report. Neurosurgery 1996 38:203 207.
28. Paczkowski FA, Sharpe IA, Sebastien D, Lewis RJ. χ-Contoxin and tricyclic antidepressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem 2007 282:17837 17844.
29. Nunez E, Lopez-Corcuera B, Vazquez J, Gimenez C, Arogon C. Differential effects of the tricyclic antidepressant amoxapine on glycine uptake mediated by the recombinant GLYT1 and GLYT2 glycine transporters. Br J Pharmacol 2000 129:200 206.
30. Nielsen CK, Lewis RJ, Alewood D et al. Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005 118:112 124.
31. Allen JW, Hofer K, McCumber D et al. An assessment of the antinociceptive efficacy of intrathecal and epidural contulakin-G in rats and dogs. Anesth Analg 2007 104:1505 1513.
32. Pharma Marketletter. Oct. 10, 2005. ECNext Inc.
33. BioSpace.Com. Cognetix Inc. 08/30/2005.
34. Smith MT, Cabot PJ, Ross FB, Robertson AD, Lewis RJ. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002 96:119 127.